Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I

Cell Growth and Differentiation

Volumn 9, Issue 1, 1998, Pages 71-78

  D'Avis, Patricia Y ^a,b   Robertson, Scott C ^a   Meyer, April N ^a   Bardwell, Wendy M ^a   Webster, Melanie K ^a   Donoghue, Daniel J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Telios Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR; MUTANT PROTEIN; PHOSPHOTRANSFERASE; TYROSINE;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; DISULFIDE BOND; ENZYME ACTIVITY; GENE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; THANATOPHORIC DWARFISM;

3T3 CELLS; ANIMALS; COS CELLS; DIMERIZATION; HUMANS; MICE; MUTATION; PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; THANATOPHORIC DYSPLASIA; TRANSCRIPTION, GENETIC;

EID: 0031985174     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Tavormina P. L., Shiang, R., Thompson, L. M., Zhu, Y-Z., Wilkin, D. J., Lachman, R. S., and Wilcox, W. R. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat. Genet., 9: 321-328, 1995.
2. Tavormina, P. L., Rimoin, D. L., Cohn, D. H., Zhu, Y-Z., Shiang, R., and Wasmuth, J. J. Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Hum. Mol. Genet., 4: 2175-2177, 1995.
3. Rousseau, F., Saugier, P., Le Merrer, M., Munnich, A., Delezoide, A-L., Maroteaux, P., Bonaventure, J., Narcy, F., and Sanak, M. Stop codon FGFR3 mutations in thanatophoric dwarfism type 1. Nat. Genet., 10: 11-12, 1995.
4. Rousseau, F., El Ghouzzi, V., Delezoide, A-L., Legeai-Mallet, L., Le Merrer, M., Munnich, A., and Bonaventure, J. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type 1 (TD1). Hum. Mol. Genet., 5: 509-512, 1996.
5. Shah, K., Astley, R., and Cameron, A. H. Thanatophoric dwarfism. J. Med. Genet., 10: 243-252, 1973.
6. Muenke, M., Schell, U., Hehf, A., Robin, N. H., Losken, H. W., Schinzel, A., Pulleyn, L. J., Rutland, P., Reardon, W., Malcolm, S., and Winter, R. M. A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nat. Genet., 8: 269-274, 1994.
7. Wilkie, A. O. M., Slaney, S. F., Oldridge, M., Poole, M. D., Ashworth, G. J., Hockley, A. D., Hayward, R. D., David, D. J., Pulleyn, L. J., Rutland, P., Malcolm, S., Winter, R. M., and Reardon, W. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat. Genet., 9: 165-172, 1995.
8. Bellus, G. A., Gaudenz, K., Zackai, E. H., Clarke, L. A., Szabo, J., Francomano, C. A., and Muenke, M. Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant cranio-synostosis syndromes. Nat. Genet., 14: 174-176, 1996.
9. Przylepa, K. A., Paznekas, W., Zhang, M., Golabi, M., Bias, W., Bamshad, M. J., Carey, J. C., Hall, B. D., Stevenson, R., Orlow, S., Cohen, M. M., and Jabs, E. W. Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome. Nat. Genet., 13: 492-494, 1996.
10. Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Greico, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., and Di Fiore, P. P. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science (Washington DC), 261, 381-383, 1995.
11. Asai, N., Iwashita, T., Matsuyama, M., and Takahashi, M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol. Cell. Biol., 15: 1613-1619, 1995.
12. Webster, M. K., and Donoghue, D. J. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet, 13: 178-182, 1997.
13. Webster, M. K., and Donoghue, D. J. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J., 15: 520-527, 1996.
14. Webster, M. K., D'Avis, P. Y., Robertson, S. C., and Donoghue, D. J. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for the lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol. Cell. Biol., 16: 4081-4087, 1996.
15. Naski, M. C., Wang, Q., Xu, J., and Ornitz, D. M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet., 13: 233-237, 1996.
16. Galvin, B. D , Hart, K. C., Meyer, A. N., Webster, M. K., and Donoghue, D. J. Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR) 2 and FGFR2/Neu chimeras. Proc. Natl. Acad. Sci. USA, 93: 7894-7899, 1996.
17. Neilson, K. M., and Friesel, R. E. Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome. J. Biol. Chem., 270: 26037-26040, 1995.
18. Neilson, K. M., and Friesel, R. Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains. J. Biol. Chem., 271: 25049-25057, 1996.
19. Chesi, M., Nardini, E., Brents, L. A., Schrock, E., Ried, T., Kuehl, W. M., and Bergsagel, P. L. Frequent translocation t(4:14)(p16-3;q32-3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet., 16: 260-264, 1997.
20. Webster, M. K., and Donoghue, D. J. Enhanced signaling and morphological transformation by a membrane-localized derivative of the FGFR3 kinase domain. Mol. Cell. Biol., 17: 5739-5747, 1997.
21. Sorokin, A., Lemmon, M. A., Ullrich, A., and Schlessinger, J. Stabilization of an active dimeric form of the epidermal growth factor receptor by introduction of an inter-receptor disulfide bond. J. Biol. Chem., 269: 9752-9759, 1994.
22. Yoshimura, A., Longmore, G., and Lodish, H. F. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormoneindependent activation and tumongenicity. Nature (Lond.), 348: 647-649, 1990.
23. Watowich, S. S., Yoshimura, A., Longmore, G. D., Hilton, D. J., Yoshimura, Y., and Lodish, H. F. Homodimerization and constitutive activation of the erythropoietin receptor. Proc. Natl. Acad. Sci. USA, 89: 2140-2144, 1992.
24. Burke, C. L., Lemmon, M. A., Coren, B. A., Engelman, D. M., and Stern, D. F. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation. Oncogene, 14: 687-696, 1997.
25. Superti-Furga, A., Eich, G., Bucher, H. U., Wisser, J., Giedion, A., Gitzelmann, R., and Steinmann, B. A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. Eur. J. Pediatr., 154: 215-219, 1995.
26. Ikegawa, S., Fukushima, Y., Isomura, M., Takada, F., and Nakamura, Y. Mutations of the fibroblast growth factor receptor-3 gene in one familial and six sporadic cases of achondroplasia in Japanese patients. Hum. Genet., 96: 309-311, 1995.
27. Thompson, L. M., Raffioni, S., Wasmuth, J. J., and Bradshaw, R. A. Chimeras of the native form or achondroplasia mutant (G375C) of human fibroblast growth factor receptor 3 induce ligand-dependent differentiation of PC12 cells. Mol. Cell. Biol., 17: 4169-4177, 1997.
28. Keegan, K., Johnson, D. E., Williams, L. T., and Hayman, M. J. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc. Natl. Acad. Sci. USA, 88: 1095-1099, 1991.
29. Maher, D. W., Strawn, L. M., and Donoghue, D. J. Alanine mutagenesis of conserved residues in the platelet-derived growth factor family: identification of residues necessary for dimerization and transformation. Oncogene, 8: 533-541, 1993.
30. Bargmann, C. I., Hung, M-C., and Weinberg, R. A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell, 45: 649-657, 1986.
31. Chen, C., and Okayama, H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol., 7: 2745-2752, 1987.
32. Chen, L. I., Webster, M. K., Meyer, A. N., and Donoghue, D. J. Transmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase. J. Cell Biol., 137: 619-631, 1997.
33. Hu, Q., Milfay, D., and Williams, L. T. Binding of NCK to SOS and activation of ras-dependent gene expression. Mol. Cell. Biol., 15: 1169-1174, 1995.